A human trial to evaluate the efficacy and safety of Echinacea extract on promotion of immunity enhancement

A 8 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Echinacea extract on promotion of immunity enhancement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006531

Enrollment

Registered

2021-09-03

Start date

2021-03-08

Completion date

Unknown

Last updated

2023-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : • Echinacea extract group: 2 times a day, 1 tablet once, after breakfast for 8 weeks(400 mg/day, 200 mg/day for Echinacea extract) • Placebo group: 2 times a day, 1 tablet once,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Healthy male and female volunteers between 19 and 70 years old 2) Volunteers who have received specific experimental illustration and agreed to participate in the study and provided a written content by him/herself

Exclusion criteria

Exclusion criteria: 1) Those with BMI under 18.5 kg/m2 or over 35 kg/m2 3) Those who have consumed medicine or health supplements related to immune function within 1 month before screening 4) Those who have been treated with antipsychotics within 3 months before screening 5) Those with or suspected to have alcoholism or substance abuse 6) Those who participated in other researches within 3 months before screening 7) Those with these results in diagnostic medical examination ? AST(Aspartate aminotransferase), ALT(Alanine Transaminase) > three times the normal limit ? Serum Creatinine > 2.0 mg/dL 8) Those who are pregnant or breastfeeding during this study 9) Those who did not accept implementation of the appropriate contraception method among urban elligible women 10) Those who are deemed inappropriate by the researcher

Design outcomes

Primary

Measure	Time frame
NK(Natural Killer) cell activity	—

Secondary

Measure	Time frame
Cytokines;Adverse events;Vital Sign	—

Countries

Korea, Republic of

Contacts

Public ContactDong Gi Baek

Wonkwang University. Iksan Korean Medicine Hospital

Outcome results